2 results about "Chlorobenzoates" patented technology

The invention discloses an application of a phosphodiesterase inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension, and the phosphodiesterase inhibitor is 1-(4-(2, 3-dihydro-1H-indeno [5, 6-b] furan-5 (4H)-keto) piperidine-4-yl)-4-chlorobenzoate. The phosphodiesterase inhibitor disclosed by the invention can effectively reduce pulmonary vascular remodeling caused by abnormal proliferation and migration of pulmonary artery smooth muscle cells, so that pulmonary artery pressure and right ventricular systolic pressure are remarkably reduced. The phosphodiesterase inhibitor disclosed by the invention has a prominent effect on inhibiting pulmonary vascular remodeling and right heart hypertrophy, has the effect of improving various clinical symptoms of pulmonary arterial hypertension, is superior to common pulmonary arterial hypertension treatment medicines at present, and has important significance on finding more new medicines for treating pulmonary arterial hypertension.

The application discloses flavonoid compounds with neuroprotective activity, and a preparation method and application thereof, and particularly relates to four specific ester derivatives of formononetin, namely, an allyl carbonate derivative (compound A), a 2-chlorobenzoic acid ester derivative (compound B), a cinnamic acid ester derivative (compound C), and a propionic acid ester derivative (compound D). The application significantly improves the defects of the parent compound, such as poor liposolubility, low blood-brain barrier permeability and low bioavailability, through specific ester group modification. Experiments show that the lipid-water partition coefficients and bioavailability of the four types of derivatives are significantly improved compared with the parent compound. In addition, the four types of derivatives show better neuroprotective activity than the parent compound and a positive control drug in Alzheimer's disease and Parkinson's disease models, and show a synergistic effect between the parent compound and the modification group. The application further provides a preparation method of the above compounds and application of the above compounds in preparation of drugs for treating neurodegenerative diseases.